Phase 2 N=35 DP13 - A Phase II Study in Patients With Primary Aldosteronism
Primary Aldosteronism
Primary: Change in Aldosterone-to-renin Ratio — -15.0; -7.0; -14.0; -11.8 ng*L/dL*mU — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Calcium Channel Blockade in Primary Aldosteronism
Primary Aldosteronism · Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Primary: Change in 24-hour Urinary Aldosterone Excretion Rate — 0.21 mcg/24h — p=0.96
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
Phase 2 N=14 The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
Hypertension
Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute
Phase 1 N=38 Aldosterone and the Metabolic Syndrome
Metabolic Diseases · Diabetes Mellitus · Endocrine System Diseases
Primary: Plasma Insulin — 75.4; 50.1; 43.5; 114.0 uU/ml
Phase 1 N=28 The Renin-Aldosterone Axis in Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome (POTS)
Primary: Mean Arterial Blood Pressure Change — 14; 10 mmHg
Phase 2 N=15 A Study of CIN-107 in Adults With Primary Aldosteronism
Primary Aldosteronism · Hyperaldosteronism
Primary: Number of Treatment Emergent Adverse Events — 27; 34; 101 Number of events
Phase 3 N=61 Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ADPKD
Primary: Change From Baseline in Flow Mediated Dilation at 6 Months. — -0.2; -0.4 Percent change.
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
N/A N=38 Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
Obesity · Insulin Resistance
Primary: Change From Baseline in Post-ischemic Dilatation — 9.6; 10.2; -1.2; -2.0 percent dilalation
N/A N=23 Aldosterone and Glucose Homeostasis
Diabetes Mellitus
Primary: Insulin Secretion — 48.9; 37.6; 51.8; 34.4 uU/mL
N/A N=41 The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
Hyperparathyroidism
Primary: Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration — 70.9; 32.5 pg/mL — p=0.049
Phase 4 N=90 Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN
Hypertension · Genetics Hypertension
Primary: Systolic /Diastolic Supine Morning Liberal Salt Automated Blood Pressure — 144.2; 148.5; 86.0; 91.4 mm hg — p=0.823
Phase 3 N=3,445 Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
Cardiovascular Diseases · Heart Diseases · Heart Failure, Congestive
Primary: Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First — 6.6; 5.9 Events…
Phase 4 N=44 Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism
Metabolic Syndrome
Primary: Insulin Secretion — 293.1; 234.7; 330.8; 300.4 uU/mL*10min
Phase 4 N=16 Effect of Aldosterone on Energy Starvation in Heart Failure
Heart Failure · Nonischemic Dilated Cardiomyopathy
Primary: Left Ventricular Work-metabolic Index (WMI) at Baseline — 7.4 (x10^6), mL x mm Hg/m^2
Phase 2 N=295 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Hyperkalemia · Resistant Hypertension
Primary: Number of Participants Remaining on Spironolactone at Week 12 — 126; 98 Participants — p=<0.0001
Phase 3 N=137 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Phase 3 N=119 The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
Arterial Hypertension · Hypertension, Resistant to Conventional Therapy · Diabetes Mellitus
Primary: Change of of Systolic Blood Pressure — -9.6; -0.7 mm Hg
N/A N=69 Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
Type 2 Diabetes Mellitus · Vascular Disease
Primary: Change in Coronary Flow Reserve From Baseline to 6 Months — 0.33; -0.10; 0.02 ratio
Phase 4 N=79 Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial
Atherosclerosis
Primary: Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo — 0.5; 7.3 percentage change — p=0.0293
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
Phase 2 N=8 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
Phase 2 N=48 A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
Uncontrolled Hypertension
Primary: Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test — 0; 0; 26; 15 Participants
Phase 3 N=15 The Role of Mineralocorticoid Receptors in Vascular Function
Apparent Mineralocorticoid Excess (AME)
Primary: Forearm Blood Flow — 1.87; 1.34 ml/100ml of tissue/min
Phase 3 N=41 Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Primary Hyperparathyroidism
Primary: Change in Parathyroid Hormone Levels — 4.0; -3.7; 0.8 pg/mL — p=0.84
Phase 3 N=20 Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
Heart Failure
Primary: Change in Body Weight — -1.9; -1.9 kilogram
Phase 2 N=59 Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Chronic Kidney Disease
Primary: Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 — -1.755; -9.253 mmHg
Phase 2 N=19 Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
Chronic Kidney Disease · Albuminuria
Primary: Difference in 24 Hour Ambulatory Systolic Blood Pressure — 7.7; 12.5 mm Hg